Physician profile
Timothy E Knight
NPI 1568536126
$6,996.30
in general payments reported to CMS, 2019-2025
36 companies · $706 in 2025
The $706 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,522 · 2020: $986 · 2021: $1,108 · 2022: $1,006 · 2023: $839 · 2024: $828 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,381.29 | 2019-2025 | |
| Janssen Biotech, INC. | $573.01 | 2019-2024 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $465.06 | 2019-2023 | Dupixent |
| Pfizer INC. | $368.01 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $345.80 | 2019-2025 | |
| Lilly USA, LLC | $303.49 | 2019-2023 | Taltz, Olumiant |
| Genzyme Corporation | $286.62 | 2019-2024 | |
| Amgen INC. | $272.78 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $255.84 | 2019-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $250.63 | 2019-2025 | Cabtreo |
| Genentech USA, INC. | $219.86 | 2019-2024 | Erivedge |
| Sun Pharmaceutical Industries INC. | $180.24 | 2019-2024 | |
| Galderma Laboratories, L.P. | $160.67 | 2019-2025 | Aklief, Nemluvio |
| Dermavant Sciences, INC. | $123.30 | 2023-2024 | Vtama |
| Ucb, INC. | $109.24 | 2021-2024 | Bimzelx |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $84.68 | 2019-2022 | |
| Celgene Corporation | $74.80 | 2019 | |
| Incyte Corporation | $73.08 | 2021-2023 | Opzelura |
| Organon LLC | $49.25 | 2025 | Vtama |
| Organogenesis INC. | $46.68 | 2021-2023 | Puraply |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.35 | 2022-2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $38.28 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $32.14 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $29.15 | 2019 | |
| Botanix Sb INC | $27.14 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $26.79 | 2024 | Idacio |
| Kerecis Limited | $23.04 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Alnylam Pharmaceuticals INC. | $21.55 | 2021 | |
| Vyne Pharmaceuticals INC. | $20.16 | 2021 | |
| Aclaris Therapeutics, INC. | $19.15 | 2019 | |
| Biofrontera INC. | $18.46 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Biohaven Pharmaceuticals, INC. | $18.29 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.87 | 2019 | |
| Epi Health, LLC | $14.89 | 2021 | |
| Kyowa Kirin, INC. | $14.70 | 2021 | |
| Biowound Solutions, INC. | $7.01 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.